Clinical Trials Logo

Clinical Trial Summary

Background: Most people who are referred to the EMG (Electromyography) Section of the NIH are enrolled into specific active studies. This allows researchers to learn about a range of rare neuromuscular disorders. But study criteria may not give researchers the chance to evaluate a single person or study a common symptom. Therefore, researchers want to assess people with neuromuscular disorders who are not currently enrolled in any NIH studies. They will perform tests on these individuals in the EMG Lab. Then they will create a repository of data that may be used for future research. This will help them learn more about these disorders. Objective: To retain data that is collected as part of participant visits to the NIH. Eligibility: People aged 18 and older who will be visiting the NIH for evaluation of their neuromuscular disorder. Design: Participants will be screened with a medical record review. Participants will have a physical exam. They will be evaluated for their neuromuscular disorder. They may have tests to learn more about how their nerves and muscles work that are called nerve conduction and EMG studies. Their muscles and nerves may be assessed with an ultrasound. Their ability to sweat may be measured. Their heart rate and blood pressure may be taken. Changes to their breathing or changes in their body position may be measured. Participant data will be given a unique numerical identifier that can be used if the data is shared. Data will be stored on a server and in a database. Participants will have 1-2 visits. Each visit will last less than 4 hours. They may be contacted for a follow-up visit.


Clinical Trial Description

PROTOCOL SUMMARY Title: Data Collection for Standard Care of Patients in the EMG Section Study Description: This protocol is designed to provide a repository of information for future hypothesis generation. We will be evaluating patients with neuromuscular disorders that are not currently enrolled in any NIH protocols with procedures performed in the EMG Lab. The procedures include standard neurophysiological studies of EMG, autonomic nervous system (ANS) testing, and neuromuscular ultrasound (NMUS) as deemed necessary for appropriate diagnostic and clinical status testing. This will allow us to investigate into the problems of these patients with the purpose of furthering general knowledge of neuromuscular disorders and enhancing our EMG capabilities. Our ability to evaluate patients with a wide variety of neuromuscular diseases is also critical to maintaining our accreditation with the clinical neurophysiology fellowship programs and training our fellows to be competent physicians, as well as for keeping all staff, including senior staff, up-to-date and familiar with the evaluation of patients with a wide spectrum of diseases. We may also be able to later refer these patients into treatment protocols or re-evaluate patients that are no longer in an active NINDS protocol. This protocol will be valuable resource to the community by engendering greater interaction with the local neurologists and clinics as well as providing certain types of neurophysiological testing that are not readily available in the community. Objectives: To provide a repository of information on enrolled participants to allow for hypothesis generation in future research To add value to the Clinical Neurophysiology training programs by providing consult, diagnostic tests, and medical follow-up of participants Endpoints: To provide a repository of information on enrolled participants to allow for hypothesis generation in future research. Study Population: The study population includes patients, male or female, who are age 18 or older with no upper age limit restrictions. The study population will be limited to 200. They may have neuromuscular disorder or neurodegenerative disorder. Description of Sites/Facilities Enrolling Participants: NINDS Intramural Clinical Research Program located in the NIH Clinical Center, Bethesda, MD. Study Duration: Participant Duration: The current estimated study duration is 10 years. An extension to this study duration may be requested in the future via an amendment. There is no specific time limitation on participant visits, though many participants may have only 1-2 visits. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05041387
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact Candida Silva
Phone (301) 496-7428
Email candida.silva@nih.gov
Status Recruiting
Phase
Start date May 15, 2024
Completion date May 1, 2031

See also
  Status Clinical Trial Phase
Completed NCT03195868 - Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy N/A
Not yet recruiting NCT05565469 - Correlation Between Abdominal Wall Stimulation and Neurostimulator Tip Location N/A
Completed NCT02309164 - The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN). N/A
Completed NCT00775645 - S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy Phase 3
Completed NCT03624426 - Detection and Prevention of Nerve Injury in Shoulder Arthroplasty Surgery N/A
Withdrawn NCT03436680 - Home-Based Neurofeedback Program in Treating Participants With Chemotherapy-Induced Peripheral Neuropathy N/A
Completed NCT05691738 - Effects of Modified Otago Exercises in Individuals With Diabetic Neuropathy N/A
Completed NCT05095870 - Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
Completed NCT02615678 - Acupuncture for CIPN in Breast Cancer Patients N/A
Completed NCT02011282 - Electro-Neuro-Muscular Stimulation in ICU N/A
Recruiting NCT01774058 - The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation Phase 2
Completed NCT01135251 - Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy Phase 2
Recruiting NCT06324344 - Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy Induced Peripheral Neuropathy (CIPN) N/A
Recruiting NCT04403802 - Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy N/A
Recruiting NCT04579406 - Perioperative Adverse Cardiovascular Event in Type-2 Diabetic Patients
Recruiting NCT03881930 - Balance Rehabilitation With Modified Visual Input in Patients With Neuropathy N/A
Completed NCT03909464 - Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy
Completed NCT01523132 - Persistent Pain After Breast Cancer Treatment (PPBCT) - Risk Factors and Pathophysiological Mechanisms N/A
Completed NCT02689661 - Impact of the Metabolic Syndrome on the Incidence of Neuropathy in Obese Subjects
Terminated NCT00998738 - Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer Phase 3